Background: Serum concentrations of soluble mesothelin-related peptides (SMRP) have been reported to be higher in patients with malignant mesothelioma than in healthy subjects and in patients with non-malignant mesothelioma diseases. The aim of the present meta-analysis was to establish the overall diagnostic accuracy of the measurement of SMRPs for diagnosing malignant mesothelioma. Methods: After a systematic review of English language studies, sensitivity, specificity, and other measures of accuracy of serum SMRPs in the diagnosis of malignant mesothelioma were pooled using random-effects models. Summary receiver operating characteristic curves were used to summarize overall test performance. Results: Eleven publications from 12 studies met our inclusion criteria. The summary estimates for SMRPs in the diagnosis of malignant mesothelioma in the studies included were sensitivity 0.64 (95% confidence interval 0. 
Introduction
Malignant mesothelioma (MM) is an aggressive tumor of serosal surfaces, such as the pleura and the peritoneum, and is usually associated with previous exposure to asbestos. 1 Patients with pleural MM generally present with shortness of breath and chest pain, and those with peritoneal MM with abdominal swelling. The clinical signs of MM are unspecific, but MM is usually associated with the presence of exudative effusions.
Finding a diagnostic marker for MM is a challenging endeavor. No unique molecule has been shown to reliably define MM from benign mesothelium or metastatic carcinomas, even by profiling the expression of tens of thousands of genes on mesothelioma tissues using. 2 Immunohistochemical diagnosis of epithelioid mesothelioma in pleural biopsy or surgically resected specimens has been actively pursued, using markers such as podoplanin, calretinin, WT-1, cytokeratin 5, thrombomodulin, and mesothelin. 3 Some of these markers have indeed been helpful for confirming the diagnosis of MM and distinguishing between MM and adenocarcinoma.
Mesothelin is a 40 kDa cell surface glycoprotein that is highly expressed in MM, pancreatic cancers, ovarian cancers, and some other cancers. 4 Mesothelin is synthesized as a precursor 69 kDa protein and forms two proteins, the membrane-bound mesothelin and a soluble megakaryocyte potentiating factor. 4 Although mesothelin is bound to cell membrane, a circulating form termed soluble mesothelin has been reported to be related to abnormal splicing events leading to synthesis of a secreted protein and to an enzymatic cleavage from membrane-bound mesothelin. 5 It has been well documented that the soluble mesothelin-related peptides (SMRPs), including both soluble mesothelin and soluble megakaryocyte potentiating factor, have been found in human serum. 2 Actually, the diagnostic accuracy of SMRP detections for MM has been extensively studied, but the exact role of these detections needs to be elucidated. We performed the present metaanalysis to establish the overall diagnostic accuracy of the measurement of SMRPs for diagnosing MM.
Methods

Search strategy and study selection
We searched Embase, Ovid, Web of Science, Cochrane database, and Medline (using PubMed as the search engine) to identify suitable studies until March 8, 2008 ; no lower date limit was applied. Articles were also identified by use of the related-articles function in PubMed. References of articles identified were also searched manually. The search terms were ''mesothelin'', ''soluble mesothelin-related peptides/ SMRP'', ''megakaryocyte potentiating factor/MPF'', ''mesothelioma'', ''sensitivity and specificity'', and ''accuracy''. Although no language restrictions were imposed initially, for the full-text review and final analysis our resources only permitted review of English articles. Conference abstracts were excluded because of the limited data presented in them.
A study was included in the meta-analysis when it provided SMRP values for both sensitivity and specificity of the diagnosis of MM. The studies including at least 10 serum specimens were selected in the study, since very small studies may be vulnerable to selection bias. Publications with evidence of possible overlap of patients with other studies were discussed by L.L., H.Z.S., and Q.L.L., and only the best-quality study was used. Two reviewers (L.L. and H.Z.S.) independently judged study eligibility while screening the citations. Disagreements were resolved by consensus.
Data extraction and quality assessment
The final set of English articles was assessed independently by two reviewers (L.L. and H.Z.S.). Data retrieved from the reports included author, publication year, participant characteristics, test methods, sensitivity and specificity data, cut-off value and methodological quality.
For each study, the following characteristics of study design were also retrieved: (1) cross-sectional design (versus case-control design); (2) consecutive or random sampling of patients; (3) blinded interpretation of determination and reference standard results; and (4) prospective data collection. If no data on the above criteria were reported in the primary studies, we requested the information from the authors. If the authors did not respond to our letters, the ''unknown'' items were treated as ''No''. In addition, we assessed the methodological quality of the studies using guidelines published by the STARD (standards for reporting diagnostic accuracy, maximum score 25) initiative 6 (i.e., guidelines that aim to improve the quality of reporting in diagnostic studies) and the QUADAS (quality assessment for studies of diagnostic accuracy, maximum score 14) tool 7 (i.e., appraisal by use of empirical evidence, expert opinion, and formal consensus to assess the quality of primary studies of diagnostic accuracy).
Statistical analyses
We used standard methods recommended for meta-analyses of diagnostic test evaluations. 8 Analyses were performed using two statistical software programs (Stata, version 8.2; Stata Corporation; College Station, TX; and Meta-DiSc for Windows; XI Cochrane Colloquium; Barcelona, Spain). We computed the following measures of test accuracy for each study: sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR).
The analysis was based on a summary receiver operating characteristic (SROC) curve. 8, 9 The sensitivity and specificity for the single test threshold identified for each study were used to plot an SROC curve. 9, 10 We convert the true positive rate (TPR) and false positive rate (FPR) from each study to their logistic transforms. The method is based on the principle that there is a linear relationship between logit (TPR) and logit (FPR) where, using natural logs, logitðTPRÞZlogðTPR=½1 À TPRÞ and logitðFPRÞ ZlogðFPR=½1 À FPRÞ:
To estimate an SROC curve, we use the linear model:
The model can be transformed back to the conventional axes of TPR against FPR, with SROC curves drawn only over the range of the data.
The model shown in the above equation (D Z a þ bS ) can be fit using conventional least squares methods (after adding 0.5 to each cell of the cross-classification of test and reference standard to deal with the possibility of zero cells) unweighted, i.e. giving equal weights to each study, or weighted by the inverse of the variance of D. A randomeffects model was used to calculate the average sensitivity, specificity and the other measures across studies. 11, 12 We used the Chi-square and Fisher's exact tests to detect statistically significant heterogeneity across studies. Since publication bias is of concern for meta-analyses of diagnostic studies, we tested for the potential presence of this bias using funnel plots and the Egger test. 13 
Results
After independent review, 20 publications determining serum concentrations of SMRPs in patients with MM were considered to be eligible for inclusion in the analysis. Of these publications, 1 was excluded because it recruited less than 10 patients in one of study groups, 25 3 were excluded because they did not allow the calculation of sensitivity or specificity, 26e28 5 were excluded because the same authors published several reports on the same patients, and only the best-quality study was considered.
29e33 Subsequently, 11 publications 14e24 were available for analysis of diagnosis accuracy of SMRPs in MM. We noted that eight publications dealt with soluble mesothelin, 14 ,16e21,24 and the remaining three publications dealt with soluble megakaryocyte potentiating factor. 15, 22, 23 In the study by Scherpereel et al., 16 the authors compared SMRP concentrations in MM patients with those in asbestos exposed-patients with benign pleural lesions and with patients with pleural metastasis of carcinomas separately, using two different cut-off values (0.93 and 1.85 nM, respectively), we thus treated these research data as two independent studies in the meta-analysis. The clinical characteristics of these studies, along with STARD and QUADAS scores, are outlined in Table 1 . 
Quality of reporting and study characteristics
The average sample size of the included studies was 297 (range from 83 to 1086), the subjects included 717 patients with MM and 2851 non-MM. In all studies included in the metaanalysis, the diagnoses of MM patients studied were made based on cytological or/and histopathological findings. On the other hand, the etiology of control groups was quite heterogeneous (Appendix Table 1 , available online). The method of determining SMRPs in all studies was enzyme-linked immunosorbent assay.
All required data were provided in the study by Shiomi et al. 22 We contacted the corresponding authors of the remaining 10 publications through E-mail for obtaining additional data. Nine authors responded who could provide additional data for 10 studies. As shown in Appendix Table 2 (available online), in 5 of 12 studies, the study was crosssectional design. In 11 studies, all samples were collected from the consecutive or random selected patients. Four studies did not report blinded interpretation of SMRP assays independent of the reference standard. Six studies reported the study design was prospective. Totally, the quality of study design and reporting diagnostic accuracy of most studies were good, since 10 of 12 studies had higher STARD scores (!13) and 9 studies had higher QUADAS scores (!10). Fig. 1 shows the forest plot of sensitivity and specificity for 12 SMRP assays in the diagnosis of MM. The sensitivity ranged from 0.41 to 0.91 (pooled 0.64, 95% CI 0.61e0.68), while specificity ranged from 0.73 to 1.00 (pooled 0.89, 95% CI 0.88e0.90). We also noted that PLR was 7.10 (95% CI 4.44e11. 35 Post-test probability of MM was estimated by: post-test probability Z post-test odds/(1 À post-test odds), where post-test odds Z (prevalence/[1 À prevalence]) Â likelihood ratio. As shown in Table 2 , when pre-test probability of MM is 10% (a hypothetical low-risk patient, which is the approximate variation in the reported studies) and when SMRP result is positive, estimated post-test probability is 43.8%. A negative test result practically excludes MM (post-test probability, 3.8%). For a patient with 25% pre-test risk, a positive test result increases the probability to 70.1%. The absence of higher SMRP concentration decreases the disease probability to 11.5%. For a high-risk patient (pre-test probability, 50%), the post-test probability of MM is 87.7%. A graph of the SROC curve for the SMRP determination showing TPRs versus FPRs from individual studies are shown in Fig. 2 . As a global measure of test efficacy we used the intersection point of the SROC curve with a diagonal line from the left upper corner to the right lower corner of the ROC space, which corresponds to the highest common value of sensitivity and specificity for the test. This point does not indicate the only or even the best combination of sensitivity and specificity for a particular clinical setting, but represents an overall measure of the discriminatory power of a test. Our data showed that the SROC curve is not positioned near the desirable upper left corner of the SROC curve, and that the maximum joint sensitivity and specificity was 0.76 (SEM, 0.05); while area under curve (AUC) was 0.82 (SEM, 0.06), indicating level of overall accuracy was not as high as expected.
Diagnostic accuracy
Appendix Table 3 (available online) shows the overall diagnostic accuracy of serum SMRP for differential diagnosis of patients with MM and healthy subjects, as well as of patients with MM and those with the other pulmonary diseases. Based on the comparison of sensitivity, specificity, PLR, NLR, DOR and AUC, the overall accuracy of SMRP determination for the diagnosis of MM seemed to be somehow better when comparing only healthy people to MM. On the other hand, the differential diagnostic role of SMRP was not so good when comparison was made between MM and other pulmonary diseases.
Publication bias
Evaluation of publication bias showed that the Egger test was significant (p Z 0.018). The funnel plots for publication bias also show some asymmetry (Fig. 3) . These results indicate a potential for publication bias.
We did not use STARD and QUADAS scores to perform the meta-regression analysis to assess the effect of study quality on relative DOR of SMRP in the diagnosis of MM due to limited numbers of the studies included. Because of the same reason, we could not explore whether or not study design such as blinded, cross-sectional, consecutive/random and prospective design affect diagnostic accuracy, either.
Discussion
In the present meta-analysis, our results indicate that determining concentrations of serum SMRPs produce consistent results with relative high specificity 0.89 (95% CI 0.88e0.90); the summary estimate of sensitivity, however, was only 0.64 (95% CI 0.61e0.68), showing that sensitivity estimates were quite low, and were more variable than specificity. These data suggest that SMRP determination might be somehow helpful in confirming (ruling in) MM. However, these tests maximize specificity at the cost of sensitivity, and this trade-off has significant clinical implications. By contrast with the higher specificity, SMRPs had low sensitivity that was not sufficiently low to exclude non-MM when a patient's SMRP concentrations are lower than the cut-off values.
The pre-test probability of MM should be considered in interpreting SMRP results for management decisions. Medical history, physical examination, radiographic evaluation, thoracentesis or closed pleural biopsy 1 may help determine the pre-test probability. Our estimate of post-test probability has considerable uncertainty. When the predicted probability of MM is low ( 10%), negative SMRP result might be somehow helpful for ruling out MM; however, positive result is inconclusive. When the pre-test risk is quite high (50%), further diagnostic procedures are unavoidable for documentation or exclusion of MM. In these cases, SMRPs are probably meaningful only for high-risk patients who do not agree to biopsy; if SMRP results are positive.
Unlike a traditional ROC plot that explores the effect of varying thresholds (cut points for determining test positives) on sensitivity and specificity in a single study, each data point in the SROC plot represents a separate study. The SROC curve presents a global summary of test performance, and shows the trade-off between sensitivity and specificity. The results of analysis based SROC curve showed the maximum joint sensitivity and specificity was 0.76; while AUC was 0.82, indicating level of overall accuracy was not as high as expected.
The DOR is a single indicator of test accuracy 34 that combines the data from sensitivity and specificity into a single number. The DOR of a test is the ratio of the odds of positive test results in the diseased relative to the odds of positive test results in the non-diseased. The value of a DOR ranges from 0 to infinity, with higher values indicating better discriminatory test performance (higher accuracy). A DOR of 1.0 indicates that a test does not discriminate between patients with the disorder and those without it. In the present meta-analysis, we have found that the mean DOR was 19.35, indicating that SMRP assays seemed to be helpful in the diagnosis of MM. The diagnostic accuracy of SMRP determination for MM seems to be similar to those of conventional tests such as cytological examination e high specificity and low sensitivity. This similarity might make SMRP determination less useful in practice because they do not have test properties that complement the properties of conventional tests.
Since the SROC curve and the DOR are not easy to interpret and use in clinical practice, and since likelihood ratios are considered more clinically meaningful, 35, 36 we also presented both PLR and NLR as our measures of diagnostic accuracy. Likelihood ratios of greater than 10 or less than 0.1 generate large and often conclusive shifts from pre-test to post-test probability (indicating high accuracy). 33 A PLR value of 7.10 suggests that patients with MM have about 7-fold higher chance of being SMRP assay-positive compared with patients without MM, and this was not high enough for the clinical purpose. On the other hand, NLR was found to be 0.39 in the present meta-analysis. If the SMRP assay result was negative, the probability that this patient has MM is 39%, which is not low enough to rule out MM.
An important strength of our study was its comprehensive search strategy. Screening, study selection, and quality assessment were done independently and reproducibly by two reviewers. We reduced the problem of missing data by contacting authors. We also explored heterogeneity and potential publication bias in accordance with published guidelines. Our meta-analysis had several limitations. Exclusion of conference abstracts may have led to publication bias, which may also be introduced by inflation of diagnostic accuracy estimates since studies that report positive results are more likely to be accepted for publication. Indeed, we observed a publication bias in the present meta-analysis.
It should be mentioned that the way of diagnosing MM was quite heterogeneous among the studies included, and some MM patients were diagnosed just based on the cytological findings. The current International Panel of pathologists does not recommend based on cytological samples alone because of the high risk of diagnostic error. 37 Thoracoscopy with multiple biopsies is preferred, allowing a diagnosis in more than 90% of cases. In all studies but not the one reported by Creaney et al., 18 the epithelioid subtype of MM was the most common pathological type. Totally, 57.2% (410/717) MM were epithelioid subtype (ranged from 29.9% to 100%). Analysis in terms of histologic type has shown that serum levels of SMRPs were significantly elevated in epithelioid subtype MM than other types. 14, 16, 22 This could explain partly the quite low sensitivity of the marker in MM diagnosis. On the other hand, control groups were very heterogeneous from one study to another and might also in part modify the marker performances. All these elements suggest to precise what could be the target population to assess the serum SMRP values in MM diagnosis, and this requires further research in the future.
In conclusion, serum SMRP determination plays a role in the diagnosis of malignant mesothelioma. The results of SMRP assays should be interpreted in parallel with clinical findings and the results of conventional tests.
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